Home  /  Resource Library  /  Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study

Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study

Results of a study comparing acalabrutinib versus chlorambucil with rituximab for first line CLL.